Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

Apr 24 2018

• By Mandy Jackson

Rheumatology

Related Content

AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study

Apr 10 2018

Lilly's Baricitinib Wins US FDA Panel Thumbs Up For One Of Two Doses

Apr 24 2018

Lilly's Baricitinib: US FDA Panel To Weigh Thrombosis Risk, Dose Selection

Apr 20 2018

Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Dec 16 2016

Another Positive Phase III For Lilly's, Incyte's Baricitinib

Sep 30 2015

Lilly licenses anti-inflammatory from Incyte in deal worth up to $755 million

Dec 21 2009

Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All

Aug 30 2017

Related Companies

Eli Lilly and Company

Pfizer Inc.

Incyte Corporation

AbbVie Inc.

Additional Topics

Advisory Committees Drug Safety Inflammation Immune Disorders BioPharmaceutical

More from Immunological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window